TD Capital Management’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

TD Capital Management’s Portfolio IDNA Stock Details IDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-237	Closed	-$4.85K	–	741
2025 Q1	$4.85K	Hold	237	–	–	﹤0.01%	387
2024 Q4	$5.36K	Buy	237 +1	+0.4%	+$24	﹤0.01%	345
2024 Q3	$5.8K	Hold	236	–	–	﹤0.01%	326
2024 Q2	$5.45K	Buy	236 +2	+0.9%	+$47	﹤0.01%	309
2024 Q1	$5.64K	Hold	234	–	–	﹤0.01%	317
2023 Q4	$5.39K	Buy	234 +1	+0.4%	+$20	﹤0.01%	320
2023 Q3	$4.75K	Sell	233 -87	-27%	-$1.95K	﹤0.01%	330
2023 Q2	$7.48K	Hold	320	–	–	﹤0.01%	298
2023 Q1	$7.44K	Sell	320 -2,198	-87%	-$55K	﹤0.01%	290
2022 Q4	$63.4K	Sell	2,518 -4,401	-64%	-$118K	0.01%	150
2022 Q3	$183K	Buy	+6,919	New	+$214K	0.03%	86
2022 Q1	–	Sell	-900	Closed	-$39K	–	215
2021 Q4	$39K	Buy	900 +5	+0.6%	+$237	﹤0.01%	176
2021 Q3	$45K	Hold	895	–	–	0.01%	164
2021 Q2	$47K	Buy	895 +41	+5%	+$1.92K	0.01%	154
2021 Q1	$39K	Hold	854	–	–	0.01%	156
2020 Q4	$39K	Buy	+854	New	+$36.9K	0.01%	144

Other funds holding IDNA

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PGA

Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

CCA

Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

TD Capital Management's IDNA Position: Q2 2025 in Review

TD Capital Management sold out of iShares Genomics Immunology and Healthcare ETF (IDNA) in Q2 2025, closing a stake of 237 shares — an estimated $4.85K sold.

TD Capital Management first reported a position in IDNA in Q4 2020 and held it in 16 quarters. The position peaked at $183K in Q3 2022. 47 funds tracked by Wall St. Rank hold IDNA as of Q2 2025.

TD Capital Management reported no remaining iShares Genomics Immunology and Healthcare ETF position as of Q2 2025 after selling out during the quarter.
TD Capital Management sold 237 iShares Genomics Immunology and Healthcare ETF shares in Q2 2025, an estimated $4.85K.
TD Capital Management first reported a position in iShares Genomics Immunology and Healthcare ETF in Q4 2020 and held it in 16 quarters.
TD Capital Management's iShares Genomics Immunology and Healthcare ETF position peaked at $183K in Q3 2022.
47 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q2 2025.

Based on TD Capital Management's 13F filing for Q2 2025, filed 8 Aug 2025.